ReviewInfection and drug resistance2017
Current perspective on emergence, diagnosis and drug resistance in
Review in Infection and drug resistance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.
- Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen.MicrobiologyOpen · 2018Pooled it
- Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2023Trial
- Pharmacological advances inJournal of enzyme inhibition and medicinal chemistry · 2026Review
- Review of the Microbial Spectrum of Mixed Respiratory Fungal Infections.Journal of epidemiology and global health · 2026Review
- β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.NPJ vaccines · 2026Article
- Mortality ofJournal of fungi (Basel, Switzerland) · 2026Article
- Inhibiting Mrt4-rRNA interaction with fumaramidmycin-based derivatives as an antifungal strategy.Nature communications · 2026Article
- Analysis of Candida auris resistance and associated risk factors in hospitalized patients at a tertiary care hospital in China.Scientific reports · 2025Article
- Managing Candida auris in dialysis units: challenges, strategies, and future directions.International urology and nephrology · 2025Review
- β-Glucan Chitosan Particle Provides Cross-Protection Against Multi-Drug- Resistant Candida auris.Research square · 2025Article
- Comparative analyses of the biological characteristics, fluconazole resistance, and heat adaptation mechanisms ofApplied and environmental microbiology · 2025Article
- Relationships BetweenPathogens (Basel, Switzerland) · 2025Article
- Genomics insights of candidiasis: mechanisms of pathogenicity and drug resistance.Frontiers in microbiology · 2025Review
- Pyrvinium Pamoate Synergizes with Azoles in vitro and in vivo to Exert Antifungal Efficacy AgainstInfection and drug resistance · 2025Article
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- TheHealth science reports · 2024Article
- Pathogenesis, Prophylaxis, and Treatment ofBiomedicines · 2024Review
- The Emergence ofInfection and drug resistance · 2024Article
- Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation to Elucidate the Molecular Targets and Potential Mechanism ofPathogens (Basel, Switzerland) · 2023Article
- Mortality Caused byJournal of fungi (Basel, Switzerland) · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.